Business Goes On For AstraZeneca, Even After Pfizer
AstraZeneca’s business development executives sit down with “The Pink Sheet” and talk about their process, almost being acquired, and partnering at the BIO convention in 2014.
You may also be interested in...
BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back
With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.